Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Johnson & Johnson and keeping the price target at $275.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asad Haider has given his Buy rating due to a combination of factors tied to Johnson & Johnson’s emerging autoimmune portfolio, anchored by Imaavy. He views the recent FDA Priority Review in warm autoimmune hemolytic anemia and the prior approval in generalized myasthenia gravis as establishing early momentum in what could become a multi-indication franchise.
He also highlights encouraging Phase 2 data in lupus, which, alongside other planned readouts over the next 12–18 months, could substantially reduce development risk and expand the drug’s addressable market. In Haider’s view, the market is still not fully reflecting Imaavy’s long-term potential, as evidenced by his higher peak sales estimate relative to consensus, and this underappreciated growth is key to supporting Johnson & Johnson’s goal of reaching double‑digit revenue growth by the end of the decade, justifying his unchanged $275 price target and Buy rating.
In another report released on April 26, Citi also reiterated a Buy rating on the stock with a $285.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JNJ in relation to earlier this year.